We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register to chat with like-minded investors on our interactive forums.
The current KRYS market cap is 4.61B. The company's latest EPS is USD 0.3801 and P/E is 423.73.
| Quarter End | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Revenue | 8.56M | 42.14M | 45.25M | 70.29M | 83.84M |
| Operating Income | -25.99M | 3.14M | -6.68M | 8.57M | 22.43M |
| Net Income | 80.75M | 8.69M | 932k | 15.57M | 27.18M |
| Year End 31 December 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Revenue | 0 | 0 | 0 | 0 | 50.7M |
| Operating Income | -22.08M | -33M | -68.28M | -145.2M | -109.73M |
| Net Income | -19.09M | -32.17M | -69.57M | -139.98M | 10.93M |
| Quarter End | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Assets | 790.35M | 818.36M | 853.3M | 917.66M | 982.32M |
| Total Liabilities | 34.4M | 39.71M | 54.05M | 78.77M | 96.47M |
| Total Equity | 755.95M | 778.64M | 799.24M | 838.89M | 885.85M |
| Year End 31 December 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Assets | 209.02M | 310.84M | 626.3M | 558.45M | 818.36M |
| Total Liabilities | 6.11M | 18.76M | 32.72M | 36.22M | 39.71M |
| Total Equity | 202.91M | 292.08M | 593.58M | 522.23M | 778.64M |
| Quarter End | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Operating | -81.57M | -88.8M | 15.89M | 11.72M | 70.58M |
| Investing | 92.8M | 82.64M | -25.98M | -45.33M | -79.66M |
| Financing | 200.13M | 202.75M | 10.58M | 21.22M | 24.59M |
| Year End 31 December 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Operating | -18.71M | -26.08M | -47.94M | -100.57M | -88.8M |
| Investing | -4.97M | -11.18M | -226.77M | -114.08M | 82.64M |
| Financing | 107.53M | 118.02M | 347.69M | 35.35M | 202.75M |
| Market Cap | 4.61B |
| Price to Earnings Ratio | 423.73 |
| Price to Sales Ratio | 91.37 |
| Price to Cash Ratio | 12.93 |
| Price to Book Ratio | 5.95 |
| Dividend Yield | - |
| Shares Outstanding | 28.76M |
| Average Volume (1 week) | 203.03k |
| Average Volume (1 Month) | 248.09k |
| 52 Week Change | 39.58% |
| 52 Week High | 219.34 |
| 52 Week Low | 107.50 |
| Spread (Intraday) | 11.1 (6.45%) |
| Company Name | Krystal Biotech Inc |
| Address |
corporation trust center wilmington, delaware 19801 |
| Website | https://www.krystalbio.com |
| Industry | biological pds,ex diagnstics (2836) |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
